The Asia Pacific human microbiome market size is expected to reach US$ 703.84 million by 2031 from US$ 124.10 million in 2023. The market is estimated to record a CAGR of 24.2% from 2023 to 2031.
Executive Summary and Asia Pacific Human Microbiome Market Analysis:
The Asia Pacific human microbiome market is segmented into Australia, China, India, Japan, South Korea, and the Rest of Asia Pacific. Factors such as increase in the incidence of metabolic disorders, a rise in demand for gene mutation and drug development research, and strategic partnerships by market players are driving the market in Asia Pacific. Furthermore, government funding and awareness initiatives in the field of human microbiome are contributing to the market growth.
Asia Pacific Human Microbiome Market Strategic Insights
Key segments that contributed to the derivation of the Asia Pacific human microbiome market analysis are type, application, and disease type.
- Based on type, the Asia Pacific human microbiome market is bifurcated into product and software and services. The product held a larger share of the market in 2023.The product segment is further sub segmented into probiotics and prebiotics.
- Based on application, the Asia Pacific human microbiome market is segmented into therapeutics, diagnostics, and research. The therapeutics held the largest share of the market in 2023.
- Based on disease type, the Asia Pacific human microbiome market is segmented into obesity, diabetes, autoimmune disorder, cancer, GIT, and others. The GIT held the largest share of the market in 2023.
Asia Pacific Human Microbiome Market Outlook
The potential of the human microbiome to transform healthcare industry has led to a recent surge in investments in research and development. Trillions of bacteria, fungi, and viruses that live in and on the human body make up the human microbiome, which is essential to good health as well as the prevention and treatment of diseases. The development of therapies based on microbiomes is receiving significant funding from biotech startups and pharmaceutical companies. One of the first microbiome startups in India, Xome Life Sciences, for example, focuses on every facet of the microbiome. The company is in the field and is developing prognostic, diagnostic, and therapeutic tools based on microbiomes to help people live healthier lives and make better decisions about their health. A recent FDA-approved treatment developed by Seres Therapeutics for recurrent Clostridium difficile infection is one of the many gastrointestinal diseases targeted by microbiome-based drugs. Vedanta Biosciences raised substantial money to build their pipeline of immunotherapies derived from microbiomes for autoimmune disorders and cancer. Notable investors such as Seventure Partners and Flagship Pioneering are actively funding companies that analyze microbiome data, reflecting a growing recognition of the microbiome's role in health. Thus, significant investment in research and development likely drives advancements in precision medicine and therapeutic interventions, thereby creating ample opportunities in the market.
Asia Pacific Human Microbiome Market Country Insights
Based on country, the Asia Pacific human microbiome market comprises China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China held the largest share in 2023.
New pharmaceuticals in the pipeline, product development and enhancement, and an increase in strategic partnerships are significant factors benefiting the microbiome therapies market in China. Xbiome Inc., a leading AI-driven microbiome therapeutics firm, acquired the clinical-stage M201 program from Assembly Biosciences, Inc., a clinical-stage biotechnology company involved in developing cutting-edge treatments for viral disorders such as hepatitis B. The increasing prevalence of target disorders is expected to drive the growth of the human microbiome market. In China, in the future, as research continues to reveal the significant role of the human microbiome in various health conditions, there is a growing interest in developing microbiome-based therapies. This is particularly true for conditions such as gastrointestinal disorders, autoimmune diseases, and metabolic disorders, where the microbiome's influence is well-established. The potential of microbiome therapeutics as more effective and personalized treatments presents a promising opportunity for market expansion. Chinese people have an IBS prevalence of 2.3–15.8%, according to National Institute of Health statistics released in June 2021.
Asia Pacific Human Microbiome Market Report Highlights
| Report Attribute | Details |
| Market size in 2023 | US$ 124.10 Million |
| Market Size by 2031 | US$ 703.84 Million |
| CAGR (2023 - 2031) | 24.2% |
| Historical Data | 2021-2022 |
| Forecast period | 2024-2031 |
| Segments Covered |
By Type
|
|
Regions and Countries Covered
|
|
| Asia Pacific | China, Japan, India, Australia, South Korea, Rest of Asia Pacific |
| Market leaders and key company profiles |
|
Some of the key players operating in the market include MaaT Pharma; Ferring Holdings SA; AOBiome Therapeutics Inc; Finch Therapeutics Group Inc; Seres Therapeutics Inc; Merck & Co Inc; Rebiotix, Inc.; Yakult Honsha Co., Ltd.; IFF Nutrition & Biosciences; and Synthetic Biologics, Inc. among others. These players are adopting various strategies such as expansion, product innovation, and mergers and acquisitions to provide innovative products to their consumers and increase their market share.
Asia Pacific Human Microbiome Market Research Methodology :
The following methodology has been followed for the collection and analysis of data presented in this report:
- Secondary Research
The research process begins with comprehensive secondary research, utilizing both internal and external sources to gather qualitative and quantitative data for each market. Commonly referenced secondary research sources include, but are not limited to:
- Company websites, annual reports, financial statements, broker analyses, and investor presentations.
- Industry trade journals and other relevant publications.
- Government documents, statistical databases, and market reports.
- News articles, press releases, and webcasts specific to companies operating in the market.
Note: All financial data included in the Company Profiles section has been standardized to USD. For companies reporting in other currencies, figures have been converted to USD using the relevant exchange rates for the corresponding year.
- Primary Research
The insight Partners conducts a significant number of primary interviews each year with industry stakeholders and experts to validate its data analysis and gain valuable insights. These research interviews are designed to:
- Validate and refine findings from secondary research.
- Enhance the expertise and market understanding of the analysis team.
- Gain insights into market size, trends, growth patterns, competitive dynamics, and future prospects.
Primary research is conducted via email interactions and telephone interviews, encompassing various markets, categories, segments, and sub-segments across different regions. Participants typically include:
- Industry stakeholders: Vice Presidents, business development managers, market intelligence managers, and national sales managers
- External experts: Valuation specialists, research analysts, and key opinion leaders with industry-specific expertise
Asia Pacific Human Microbiome Market Country and Regional Insights
